|
CD73-PROTACs for Cancer Therapy
SHORT DESCRIPTION
A novel first-in-class proteolysis targeting chimera (PROTAC) that selectively degrades CD73 to reverse tumor immune evasion and inhibit cancer progression.
INVENTORS
Bin Zhang*
Northwestern University Feinberg School of Medicine, Department of Medicine (Hematology & Oncology)
Gary Schiltz*
Weinberg...
Published: 7/6/2026
|
Updated: 7/6/2026
|
Inventor(s):
Keywords(s): BIO2026, Breast cancer, Cancer/Oncology, Colon cancer, Lung cancer, Melanoma, PROTAC, Targeted therapy, Therapeutics, TPD - Targeted protein degradation
Category(s): Life Sciences > Therapeutics
|
|
Protein Degraders of NSD2 for Targeted Treatment of Head and Neck Cancers
SHORT DESCRIPTION
Targeted protein degraders that selectively eliminate NSD2 for improved treatment of head and neck cancers.
INVENTORS
Gary Schiltz*
Weinberg College of Arts and Sciences, Department of Chemistry
Yanis Boumber
* Principal Investigator
NU Tech ID: NU 2023-140
IP STATUS
U.S....
Published: 6/16/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s): BIO2026, Cancer/Oncology, Head and neck cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 6/16/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, BIO2026, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081
INVENTORS
Sarki Abdulkadir (PI)*
Northwestern University Feinberg School of Medicine, Department of Urology
Gary Schiltz (PI)*
Weinberg College of Arts and Sciences, Department of Chemistry
SHORT DESCRIPTION
A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate...
Published: 6/16/2026
|
Updated: 2/3/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, BIO2026, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Compounds and methods for FBXW7-R465C-mediated protein degradation
NU 2024-224
INVENTORS
Xiaoyu Zhang*
Ananya Basu
SHORT DESCRIPTION
This invention describes novel heterobifunctional compounds that exploit a somatic mutant of the FBXW7 E3 ligase for targeted protein degradation.
BACKGROUND
Targeted protein degradation (TPD) is a powerful therapeutic strategy that harnesses the cell's natural machinery...
Published: 6/17/2026
|
Updated: 11/18/2025
|
Inventor(s):
Keywords(s): AUTM26C1, BIO2026, Cancer/Oncology, PROTAC, Targeted therapy, Therapeutics, TPD - Targeted protein degradation
Category(s): Life Sciences > Therapeutics
|
|
IDO-PROTACs for Improving the Anti-Cancer Immune Response
NU 2020-137
INVENTORS
Derek Wainwright*
Gary Schiltz
SHORT DESCRIPTION
IDO-PROTAC that target immunosuppressive IDO activity via degradation
ABSTRACT
The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy, chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...
Published: 6/16/2026
|
Updated: 5/27/2022
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, BIO2026, Brain cancer, Cancer/Oncology, Colon cancer, Endometrial cancer, Immunotherapy, Pancreatic cancer, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|